BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 19

Cabaletta Bio Inc

CABANASDAQ
Trade with Public
Trade with Public
$2.55
-0.03-1.16%
가까이에: Sep 18, 5:00 PM EST
$2.64
0.08743.43%
시간외: 7:41 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Cabaletta Bio Financials

Cabaletta Bio (CABA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from
Benzinga Newsdesk

PRO
Cabaletta Bio Q1 EPS $(0.39), Inline

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 45.07 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Newsdesk

PRO
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the
Benzinga Newsdesk

PRO
Cabaletta Bio Q3 EPS $(0.44) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Of $159.9M Provides Cash Runway Into 2H 2026

Benzinga Newsdesk

PRO
Cabaletta Bio Q2 EPS $(0.73) Misses $(0.61) Estimate

Benzinga Newsdesk

PRO
Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved